Dare Bioscience Files 8-K for Other Event

Ticker: DARE · Form: 8-K · Filed: Apr 11, 2025 · CIK: 1401914

Dare Bioscience, INC. 8-K Filing Summary
FieldDetail
CompanyDare Bioscience, INC. (DARE)
Form Type8-K
Filed DateApr 11, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 8-K, disclosure, corporate-event

TL;DR

DARE filed an 8-K for an 'Other Event' on 4/11/25 - details pending.

AI Summary

On April 11, 2025, Dare Bioscience, Inc. filed an 8-K report detailing an "Other Event." The filing does not provide specific details about the event itself, but it is a standard disclosure for significant corporate occurrences.

Why It Matters

This filing indicates a significant event has occurred for Dare Bioscience, Inc., requiring public disclosure. Investors should look for further details to understand the event's implications.

Risk Assessment

Risk Level: medium — The filing is an 8-K for an 'Other Event' without immediate disclosed specifics, creating uncertainty about the nature and impact of the event.

Key Numbers

Key Players & Entities

FAQ

What specific event is disclosed in the 8-K filing by Dare Bioscience, Inc. on April 11, 2025?

The filing is categorized under 'Other Events' and does not provide specific details about the nature of the event within the provided text.

What is the principal executive office address for Dare Bioscience, Inc.?

The principal executive offices are located at 3655 Nobel Drive, Suite 260, San Diego, CA 92122.

What is the company's telephone number?

The company's telephone number, including area code, is (858) 926-7655.

What were Dare Bioscience, Inc.'s former company names?

Dare Bioscience, Inc. was formerly known as Cerulean Pharma Inc. and Tempo Pharmaceuticals Inc.

When did the name change from Tempo Pharmaceuticals Inc. occur?

The date of the name change from Tempo Pharmaceuticals Inc. was 20070604.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 11, 2025 regarding Dare Bioscience, Inc. (DARE).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing